The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury

AKI is a very common disease in the setting of critical illness and carries an extremely high
morbidity and mortality rate (over 50%). Currently there are no FDA approved therapeutic
agents for the treatment of AKI. There is limited prospective evidence to guide nephrologists
in terms of which patients will progress to more severe AKI in the setting of early AKI.
Similarly, there is no evidence to guide nephrologists in terms of which patients will
completely recover their renal function after AKI. Thus we need to know very early in the
course of AKI which patients will progress and go on to require renal replacement therapy
(RRT). Additionally we will investigating the long term patient outcomes, 2-3 years after the
index AKI admission.

Inclusion Criteria:

1. 18 yrs or older

2. increase in serum creatinine of 0.3 mg/dl within 48 hours or an increase of greater
than or equal to 150% from baseline or sustained oliguria (UOP < 0.5 cc/kg/hr for 6
hours with the last 48hours)

3. written informed consent

4. patients with an indwelling bladder catheter

Exclusion Criteria:

1. Voluntary refusal

2. Patients with advanced chronic kidney disease - as defined by a baseline glomerular
filtration rate (GFR) < 30 ml/min (MDRD)

3. history of renal transplant

4. Pregnant patients

5. Allergy / Sensitivity to Loop diuretics (furosemide)

6. Pre-renal AKI

- defined by a Fractional Excretion of Sodium (FENa) of < 1% and no urinary casts

- under-resuscitated as per the treating clinical team

- active bleed

7. Post renal AKI

- evidence of hydro-ureter

- clinical scenario wherein obstruction is considered a likely possibility